Arbutus Biopharma Appoints Melissa V. Rewolinski to its Board

Arbutus Biopharma Appoints Melissa V. Rewolinski to its Board

Arbutus Biopharma (NASDAQ: ABUS ) Corporation (Nasdaq: ABUS) today announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 12, 2023.

“We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus. “Dr. Rewolinski brings more than 20 years of strategic, operational and drug development experience within the pharmaceutical industry. We look forward to relying on her counsel and expertise as we continue to advance our pipeline of assets directed towards a functional cure for HBV and novel treatment options for coronavirus.”

Dr. Rewolinski currently serves as principal of MVR Consulting, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies. Earlier she held a number of senior level R&D positions for Intercept, rising to Senior Vice President, Head of Technical Operations, and member of the Executive Team. Previously, she served as Senior Director, Development for Amira Pharmaceuticals, and before that as a Chemical Development Group Leader and a Pharmaceutical Sciences Project Team Leader for Pfizer Global R&D. Dr. Rewolinski began her career at Pharmacia & Upjohn as a post-doctoral research scientist. She currently serves as a board member for Lannett Company, Inc., and American Type Culture Collection (ATCC). Dr. Rewolinski earned a doctorate degree in organic chemistry and Bachelor of Science degree in chemistry, magna cum laude, from Rice University.

Dr. Rewolinski, commented, “This is an exciting time to join the Board of Arbutus. I look forward to working with my fellow Board members to support Arbutus in its continued efforts to develop treatments for HBV and coronaviruses.”

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or


Related Articles